TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26087080

Group type: EXPERIMENTAL
Intervention: Continuous terbinafine 250 mg daily for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Pulse terbinafine (3 pulses of 500 mg daily for a week, repeated every 4 weeks)
Number of subjects: 76
Study: 23777507

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 48
Study: 21629686

Group type: EXPERIMENTAL
Intervention: Spatial secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High navigational ability
Number of subjects: 0
Study: 19304253

Group type: EXPERIMENTAL
Intervention: Maternal dietary variety (fruits, vegetables, snacks, meat, dairy, soda)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Adolescent mothers who purchased groceries
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Maternal and toddler dietary variety
Number of subjects: 109
Study: 18283077

Group type: EXPERIMENTAL
Intervention: Asthma Agents System (web-based data collection system)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 290
Study: 15009861

Group type: EXPERIMENTAL
Intervention: Two coil (low RA) configuration
Number of subjects: 11

Group type: COMPARATOR
Intervention: Single coil (RV) configuration
Number of subjects: 11
Study: 11599156

Group type: EXPERIMENTAL
Intervention: Insulin lispro (L1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin lispro combined with 15% to 20% NPH (L2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular insulin treatment (Control)
Number of subjects: 30
Study: 9874860

Group type: EXPERIMENTAL
Intervention: Tramadol 25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lidocaine 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 10
Study: 7978146

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% plain
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain and triamcinolone acetonide 40 mg
Number of subjects: 30
Study: 2656626

Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 68
Study: 4376998

Group type: EXPERIMENTAL
Intervention: Intensive intravenous cyclophosphamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional oral Melphalan therapy
Number of subjects: 24
Study: 10910243

Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 27

Group type: COMPARATOR
Intervention: No stoma
Number of subjects: 27
Study: 31221354

Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 15
Study: 29039073

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control (standard antiemetic treatment)
Number of subjects: 153
Study: 26585957

Group type: EXPERIMENTAL
Intervention: Weekly messages comparing statin adherence to other participants (comparison)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Weekly summaries of statin adherence (summary)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Daily reports to Medication Adherence Partner (MAP)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Weekly reports to MAP
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Reports to MAP only if dose was missed
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 401
Study: 24469527

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy for auditory verbal hallucinations (AVHs)
Number of subjects: 41
Study: 22947847

Group type: EXPERIMENTAL
Intervention: Whitening product used twice daily for 3 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: No whitening products
Number of subjects: 62
Study: 21187549

Group type: EXPERIMENTAL
Intervention: Percutaneous transpedicular vertebroplasty using calcium phosphate cement (CPC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 36
Study: 18166121

Group type: EXPERIMENTAL
Intervention: 024 essential oil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham oil
Number of subjects: 43
Study: 16320801

Group type: EXPERIMENTAL
Intervention: Garlic (300 mg, containing 1.3% allicin, twice daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (identical tablets)
Number of subjects: 70
Study: 12030110

Group type: EXPERIMENTAL
Intervention: Interferon-α2a 3.0 μ/m2 s.c. Monday, Wednesday, and Friday weeks 1-8; interleukin-2 11 μ/m2 s.c. Tuesday, Thursday and Saturday of weeks 1-4; cis-retinoic acid 1 mg/kg po daily weeks 1-8; 5-fluorouracil 750 mg/m2 IV weekly during weeks 5-8
Number of subjects: 58
Study: 9814639

Group type: EXPERIMENTAL
Intervention: fampridine-SR 12.5 and 17.5 mg b.i.d. over a 2-week treatment period
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: fampridine-SR
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 7808737

Group type: EXPERIMENTAL
Intervention: Heart operated patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 64
Study: 2510608

Group type: EXPERIMENTAL
Intervention: Vamin 9 glucose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vaminolact
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 14
Study: 1058212

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment by grinding
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no occlusal adjustment)
Number of subjects: 29
Study: 31711085

Group type: EXPERIMENTAL
Intervention: Bone graft group (bone graft placed between the implant and inferior alveolar nerve)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (implants placed in direct contact with the inferior alveolar nerve)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 28585585

Group type: EXPERIMENTAL
Intervention: Betamethasone Gel (0.05%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lidocaine Gel (4.0%)
Number of subjects: 120
Study: 25340384

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22305297

Group type: EXPERIMENTAL
Intervention: Atovaquone (13.3mg/kg PO q 8h) and azithromycin (10-12.5mg/kg PO q 24h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19237189

Group type: EXPERIMENTAL
Intervention: Grandio bonded with Solobond
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tetric Ceram bonded with Syntac
Number of subjects: 30
Study: 17508991

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of around 0.03%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 16
Study: 15485755

Group type: EXPERIMENTAL
Intervention: Usual care plus nurse care management intervention (INT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual medical care only (UC)
Number of subjects: 150
Study: 11242726

Group type: EXPERIMENTAL
Intervention: Hytac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgam or other tooth-colored materials
Number of subjects: 0
Study: 9402170

Group type: EXPERIMENTAL
Intervention: Younger patients (< 35 years)
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Older patients (≥ 70 years)
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Middle-aged patients (35-69 years)
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: All age groups
Number of subjects: 1283
Study: 8430921

Group type: EXPERIMENTAL
Intervention: Theophylline (two dosage levels)
Number of subjects: 14
Study: 2441648

Group type: EXPERIMENTAL
Intervention: Loperamide 0.4 mg/kg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Loperamide 0.8 mg/kg/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 30350717

Group type: EXPERIMENTAL
Intervention: Ocriplasmin injection (Jetrea®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no ocriplasmin)
Number of subjects: 0
Study: 28481690

Group type: EXPERIMENTAL
Intervention: M-M-R II
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: MMR-RIT
Number of subjects: 752

Group type: COMPARATOR
Intervention: M-M-R II and MMR-RIT
Number of subjects: 752
Study: 26181705

Group type: EXPERIMENTAL
Intervention: 12-week pharmacotherapy-based algorithm treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study: 23953784

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Epidural (EPI)
Number of subjects: 65
Study: 19825842

Group type: EXPERIMENTAL
Intervention: Comprehensive community-based program
Number of subjects: 2180000

Group type: COMPARATOR
Intervention: Reference community
Number of subjects: 2180000
Study: 18573617

Group type: EXPERIMENTAL
Intervention: Behavioral continuing care adherence intervention (CPR) involving contracting, prompting, and reinforcing attendance
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard treatment (STX)
Number of subjects: 150
Study: 17213002

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered at 3, 7, and 11 pm (total daily dose, 1200 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14586357

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (2 sprays of 400 mcg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (2 sprays)
Number of subjects: 99
Study: 10758957

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization with CO2 laser (TMR) in addition to optimal medical treatment (MT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Optimal medical treatment (MT)
Number of subjects: 100
Study: 9066360

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and magnetic resonance spectroscopic imaging
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopic imaging
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Comparison of averaged metabolite and T2-weighted lesion probability images
Number of subjects: 28
Study: 8320424

Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day) + calcium (500 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 32
Study: 3549990

Group type: EXPERIMENTAL
Intervention: Adriamycin (70 mg/m2, slow push, every 3 weeks for seven courses, maximum 550 mg/m2)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 47
Study: 28497534

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) - 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 12 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no TRT)
Number of subjects: 65
Study: 27557654

Group type: EXPERIMENTAL
Intervention: Regular-fat cheese (REG)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Reduced-fat cheese (RED)
Number of subjects: 164

Group type: COMPARATOR
Intervention: No-cheese, carbohydrate control (CHO)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: All diets (REG, RED, CHO)
Number of subjects: 164
Study: 25539989

Group type: EXPERIMENTAL
Intervention: Patient education intervention involving a 2-day GP workshop and patient education sessions scheduled at 1, 4, 7, 10, 13, and 19 months.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (standard care without the intervention).
Number of subjects: 400
Study: 22460421

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study: 20403351

Group type: EXPERIMENTAL
Intervention: Indirab (Vero cell based rabies vaccine)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Verorab (reference vaccine)
Number of subjects: 561
Study: 18689364

Group type: EXPERIMENTAL
Intervention: Diet S (24 g soy protein and 70-80 mg isoflavones)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diet SD (12 g soy protein, 12 g dairy protein, and 70-80 mg isoflavones)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Diet D (24 g dairy protein without isoflavones)
Number of subjects: 91
Study: 15844839

Group type: EXPERIMENTAL
Intervention: Xiong‐gui‐tiao‐xue‐yin (Kyuki‐chouketsu‐in) at a dose of 6.0 g/day
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (no Xiong‐gui‐tiao‐xue‐yin)
Number of subjects: 268
Study: 11394426

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (group O)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg (group D)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg (group M)
Number of subjects: 200
Study: 9891192

Group type: EXPERIMENTAL
Intervention: Buccal prochlorperazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral prochlorperazine
Number of subjects: 0
Study: 7981800

Group type: EXPERIMENTAL
Intervention: First tarsometatarsal reorientation arthrodesis
Number of subjects: 0
Study: 2598991

Group type: EXPERIMENTAL
Intervention: Conventional formulation of Carbamazepine (CBZ)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of Carbamazepine (CBZ)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 19375095

Group type: EXPERIMENTAL
Intervention: Spaced education cohort
Number of subjects: 206

Group type: COMPARATOR
Intervention: Bolus cohort
Number of subjects: 206
Study: 371974

Group type: EXPERIMENTAL
Intervention: 2,3-dihydroxybenzoic acid (2,3-DHB) at a dose of 25 mg/kg four times per day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (mannitol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2,3-dihydroxybenzoic acid (2,3-DHB)
Number of subjects: 15
Study: 30844984

Group type: EXPERIMENTAL
Intervention: In-season weightlifting training (conducted biweekly for 12 weeks)
Number of subjects: 22
Study: 28704936

Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (berberine 200 mg, monacolin K 3 mg, chitosan 10 mg, coenzyme Q 10 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 26490344

Group type: EXPERIMENTAL
Intervention: Aerobic training on a bicycle ergometer for 15 minutes, 3 times per week for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isotonic exercises for 30 minutes, 3 times per week for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both interventions (aerobic and isotonic exercises)
Number of subjects: 60
Study: 24500106

Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 193

Group type: COMPARATOR
Intervention: Workbook intervention
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 193
Study: 21723044

Group type: EXPERIMENTAL
Intervention: Negative Pressure Dressing (NPD) at 80 mm Hg for four days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional dressing (Vaseline gauze and cotton pads)
Number of subjects: 30
Study: 19301720

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once a day for five days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17518967

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Traditional Amalgam (TA)
Number of subjects: 681
Study: 15195867

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 45
Study: 11270008

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9921943

Group type: EXPERIMENTAL
Intervention: Sealed group (povidone-iodine gel applied to subcutaneous tissue)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Open group (usual treatment)
Number of subjects: 59
Study: 8042237

Group type: EXPERIMENTAL
Intervention: 500 IU vitamin E orally per day for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: No vitamin E (control)
Number of subjects: 20
Study: 3281487

Group type: EXPERIMENTAL
Intervention: Proguanil (200 mg daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Chloroquine (300 mg weekly)
Number of subjects: 170
Study: 30443664

Group type: EXPERIMENTAL
Intervention: Combination of corticosteroid injections and strength training/stretching (n=29)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Strength training and stretching (n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Corticosteroid injections (n=31)
Number of subjects: 90
Study: 28160288

Group type: EXPERIMENTAL
Intervention: 2-hour cryotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6-hour cryotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melphalan exposure
Number of subjects: 0
Study: 26700861

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2a therapy for 48 weeks
Number of subjects: 22
Study: 24340290

Group type: EXPERIMENTAL
Intervention: BBTI treatment
Number of subjects: 39
Study: 20943352

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study: 19918858

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 374

Group type: COMPARATOR
Intervention: Hospital follow-up
Number of subjects: 374
Study: 17022791

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/day
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Amisulpride 150 mg/day
Number of subjects: 244
Study: 12723838

Group type: EXPERIMENTAL
Intervention: Standard def-t criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nyvad's new caries diagnostic criteria
Number of subjects: 0
Study: 11445758

Group type: EXPERIMENTAL
Intervention: Endurance-trained women (ET)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Moderately active women (MA)
Number of subjects: 14
Study: 9926802

Group type: EXPERIMENTAL
Intervention: Implantable insulin pump
Number of subjects: 51

Group type: COMPARATOR
Intervention: Multiple daily insulin injections
Number of subjects: 51
Study: 8067597

Group type: EXPERIMENTAL
Intervention: Azelastine, 2 mg bid
Number of subjects: 199

Group type: COMPARATOR
Intervention: Clemastine fumarate, 1.34 mg bid
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo bid
Number of subjects: 199
Study: 2658502

Group type: EXPERIMENTAL
Intervention: Experimental nursing homes
Number of subjects: 0
Study: 30639384

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with tocotrienol
Number of subjects: 23
Study: 28934950

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-acupuncture treatment
Number of subjects: 0
Study: 25797560

Group type: EXPERIMENTAL
Intervention: Rituximab plus daily navitoclax for 12 weeks (arm B)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Rituximab plus daily navitoclax until disease progression or unacceptable toxicity (arm C)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Rituximab (arm A)
Number of subjects: 118
Study: 22952365

Group type: EXPERIMENTAL
Intervention: Dried fermentation biomass (DFB)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine intestinal mucosa (PEP50)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Hydrolyzed porcine intestinal mucosa (PEP2+)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fish meal
Number of subjects: 92
Study: 21242774

Group type: EXPERIMENTAL
Intervention: Nurse navigator intervention
Number of subjects: 78
Study: 19695189

Group type: EXPERIMENTAL
Intervention: High-dose ganciclovir (7.5 mg/kg in inducement phase, 10 mg/kg in maintaining phase)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Low-dose ganciclovir (5 mg/kg in inducement and maintaining phases)
Number of subjects: 167
Study: 17091363

Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured within 4 weeks after treatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Treatment type (radical prostatectomy, external beam radiation, or brachytherapy)
Number of subjects: 105
Study: 14727275

Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of bupivacaine 0.25% with ketamine 0.25 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of bupivacaine 0.25% with ketamine 0.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of bupivacaine 0.25% with ketamine 1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group 1 (bupivacaine 0.25% with ketamine 0.25 mg/kg)
Number of subjects: 60
Study: 11349178

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg) and medroxyprogesterone acetate (5 mg)
Number of subjects: 208

Group type: COMPARATOR
Intervention: 17beta-estradiol (2 mg) and norethindrone acetate (1 mg)
Number of subjects: 208
Study: 9139489

Group type: EXPERIMENTAL
Intervention: Combined injection of acellular pertussis-diphtheria-tetanus vaccine with Haemophilus influenzae b conjugate vaccine
Number of subjects: 468
Study: 8375540

Group type: EXPERIMENTAL
Intervention: Polyacrylamide gel (1.5%, 1.6%, 1.7%, 1.8%)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Polyacrylamide gel (1.8%)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Human cervical mucus (CM)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard sperm analyses
Number of subjects: 169

Group type: COMPARATOR
Intervention: Postcoital testing
Number of subjects: 169
Study: 3526819

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 10
Study: 29389037

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 593

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 593
Study: 26684594

Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair (TEVAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy (anti-impulse therapy)
Number of subjects: 0
Study: 25024190

Group type: EXPERIMENTAL
Intervention: Higher-level grouping based on relative position of objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control studies for low-level grouping
Number of subjects: 0